BTIG Research Reaffirms “Buy” Rating for Organogenesis (NASDAQ:ORGO)

Organogenesis (NASDAQ:ORGO)‘s stock had its “buy” rating reaffirmed by BTIG Research in a report released on Friday,Benzinga reports. They currently have a $7.00 price target on the stock. BTIG Research’s price objective would indicate a potential upside of 70.73% from the company’s previous close.

Separately, Cantor Fitzgerald upped their price objective on shares of Organogenesis from $7.00 to $9.00 and gave the stock an “overweight” rating in a research report on Friday, August 8th. Two analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.33.

Organogenesis Stock Down 12.4%

Shares of ORGO opened at $4.10 on Friday. The business’s 50-day moving average price is $4.77 and its 200-day moving average price is $4.25. Organogenesis has a twelve month low of $2.61 and a twelve month high of $6.71. The stock has a market cap of $520.12 million, a PE ratio of -29.28 and a beta of 1.75.

Organogenesis (NASDAQ:ORGO) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.08). The company had revenue of $101.01 million for the quarter, compared to the consensus estimate of $104.75 million. Organogenesis had a negative net margin of 1.92% and a negative return on equity of 0.37%. Organogenesis has set its FY 2025 guidance at EPS. Analysts expect that Organogenesis will post -0.07 earnings per share for the current fiscal year.

Institutional Trading of Organogenesis

Several hedge funds and other institutional investors have recently bought and sold shares of the company. State of Wyoming purchased a new stake in Organogenesis in the second quarter worth approximately $319,000. Tower Research Capital LLC TRC boosted its stake in Organogenesis by 590.3% in the second quarter. Tower Research Capital LLC TRC now owns 23,655 shares of the company’s stock worth $87,000 after buying an additional 20,228 shares in the last quarter. Mink Brook Asset Management LLC purchased a new stake in Organogenesis in the second quarter worth approximately $340,000. First Light Asset Management LLC purchased a new stake in Organogenesis in the second quarter worth approximately $24,804,000. Finally, Raymond James Financial Inc. boosted its stake in Organogenesis by 5.7% in the second quarter. Raymond James Financial Inc. now owns 444,240 shares of the company’s stock worth $1,626,000 after buying an additional 23,919 shares in the last quarter. Hedge funds and other institutional investors own 49.57% of the company’s stock.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.